News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55

Al's Comment:

 They did not say how the patients did, but they did report that they were able to deliver the drug to the correct place in a higher percentage of the time than in previous trials.  That was the big problem with previous trials involving convection enhanced delivery.  In the first such trial, the PRECISE trial, it was found that most or all of the patients did not get the drug to the correct place - which didn't give the drug a chance to work - so the trial failed. More recently the Tocagen trials have used CED and have vastly improved the ability to get the drug where it needs to go. Hopefully this is another step toward getting the drug to the correct place 100% of the time.

(Disclaimer: Medicenna is a sponsor of the Musella Foundation)


Posted on: 10/10/2017

Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc